hrp0097p1-486 | Fetal, Neonatal Endocrinology and Metabolism | ESPE2023

Severe hypercalcemia due to subcutaneous fat necrosis despite minimal skin lesions in a newborn: a case report

Berkenbosch Lizanne , Straetemans Saartje

Introduction: Subcutaneous fat necrosis of the newborn (SCFN) is a self-limiting panniculitis which can develop in the first weeks of life. The disorder is characterized by firm, red or purple subcutaneous nodules and plaques on the trunk, buttocks, cheeks, and extremities and is associated with perinatal stress. SCFN may lead to hypoglycemia, anemia, thrombocytopenia, hypertriglyceridemia and hypercalcemia. The proposed mechanism for the hypercalcemia is extr...

hrp0098fc8.5 | Adrenals and HPA Axis 2 | ESPE2024

Free cortisol and free 21-deoxycortisol in the clinical evaluation of adrenal insufficiency in congenital adrenal hyperplasia

P.H. Adriaansen Bas , Utari Agustini , J. Olthaar Andre , C.B.M. van der Steen Rob , J. Pijnenburg-Kleizen Karijn , Berkenbosch Lizanne , N. Span Paul , C.G.J. Sweep Fred , L. Claahsen-van der Grinten Hedi , E. van Herwaarden Antonius

Background: Some patients with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21OHD) survive without glucocorticoid treatment, despite low total cortisol levels. This may be caused by accumulating precursor steroids such as 21-deoxycortisol (21DF), which could contribute to the glucocorticoid activity. In addition, these precursor steroids may decrease the cortisol-protein binding, thereby increasing the free (biologically activ...

hrp0097p1-318 | Growth and Syndromes | ESPE2023

15-year experience with the IGF1 generation test in the Netherlands

Kruijsen Anne , de Groote Kirsten , Punt Lauren , van Trotsenburg Paul , Pijnenburg-Kleizen Karijn , Bocco Gianni , Berkenbosch Lizanne , van Setten Petra , Claahsen - van der Grinten Hedi , van der Kaay Danielle , Schott Nina , van Tellingen Vera , van Mill Edgar , van der Heyden Josine , Brandsma Annelies , Hendriks Yvonne , Losekoot Monique , van Duyvenvoorde Hermine , Hokken-Koelega Anita , Renes Judith , Maarten Wit Jan , de Bruin Christiaan , Joustra Sjoerd

Introduction: Among children with short stature, some show persistent IGF-I levels <-2.0 SDS despite a normal growth hormone (GH) response in a stimulation test. This may be caused by conditions that could benefit from recombinant human GH (rhGH) therapy (e.g. GH neurosecretory dysfunction, bioinactive GH, partial GH insensitivity). Therefore, the IGF-I generation test (IGFIGT) was implemented in 2006 using a national, standardized protocol. Children with a...